| | | | | hand, the drug-based treatments that do work come |
| New University-Based Research Study Demonstrates | | | | with potentially serious negative side effects. This |
| A Novel Mechanism Of Action For New Hair | | | | tends to render HairGenesis® a unique proposition |
| Formulation, TS050508A | | | | in the category. " |
| Discovery Could Lead to More Effective Treatments | | | | About eCAM |
| Dateline: Rensselaer, NY, August 20, 2009 | | | | With a cited reference impact factor of 2.535, the |
| In the current issue of the peer-reviewed medical | | | | international, peer-reviewed journal Evidence-based |
| journal Evidence Based Complimentary & | | | | Complementary and Alternative Medicine (eCAM) is |
| Alternative Medicine (eCAM) scientists at The | | | | widely considered to be among the most |
| University of Albany, Center For Functional Genomics, | | | | well-respected research publications in the ISI |
| working collaboratively with Advanced Restoration | | | | category of Integrative & Complementary |
| Technologies (ART), report the positive findings of a | | | | Medicine. The Journal seeks to apply scientific rigor to |
| series of basic science experiments recently | | | | the study of complementary and alternative medicine |
| undertaken to test a novel, naturally derived hair loss | | | | (CAM) modalities. eCAM emphasizes health outcome, |
| treatment formula, TS050508A. | | | | while documenting biological mechanisms of action. |
| Because chronic inflammation of the hair follicle is | | | | The journal is devoted to the advancement of |
| considered a contributing factor in the onset and | | | | science in the field of basic research, clinical studies, |
| progression of androgenetic alopecia (AGA), study | | | | methodology or scientific theory in diverse areas of |
| investigators Sridar Chittur, Brian Parr & Geno | | | | Biomedical Sciences. eCAM is also noteworthy as a |
| Marcovici sought to measure the test material's | | | | journal that makes the final published version of |
| activity in blocking key markers of pathologic | | | | every NIH-funded paper publicly available in PubMed |
| inflammation by using a well-validated molecular assay | | | | Central no later than 12 months after publication. Such |
| representative of hair follicle keratinocytes. | | | | deposits are in accord with the NIH Public Access |
| Specifically, the research team found that the test | | | | Policy. |
| compound suppressed gene expression of several | | | | Link To New Hair Growth Formula Study |
| inflammatory chemokines potentially linked to hair | | | | About The Center For Functional Genomics, SUNY |
| loss. | | | | The Microarray Core Facility is a component of the |
| In addition to anti-inflammatory agents, TS050508A | | | | University Of Albany Center for Functional Genomics |
| was formulated with a subset of botanically derived, | | | | and was established to provide the infrastructure to |
| highly potent 5 alpha-reductase (5AR) inhibitors. 5AR | | | | enable the development of major projects that utilize |
| catalyzes the conversion of testosterone (T) to its | | | | DNA microarrays for large-scale analysis of gene |
| more pathological metabolite dihydrotestosterone | | | | expression. The DNA Microarray Center currently |
| (DHT). DHT is a well-known trigger of pattern hair | | | | employs two technologies for gene expression |
| loss. Thus, by combining targeted anti-inflammatory | | | | analysis: Affymetrix GeneChip arrays and |
| agents with potent 5AR inhibitors the test | | | | custom-produced spotted cDNA microarrays. Projects |
| composition has been designed to offer enhanced | | | | developed through the DNA Microarray Center have |
| clinical efficacy over conventional monotherapy. | | | | made use of Affymetrix arrays from both eukaryotic |
| Lead scientist for the study Sridar Chittur, Ph.D. has | | | | as well as prokaryotic genomes. The Facility is also |
| been at the forefront of molecular research authoring | | | | currently developing specialized custom printed arrays |
| published works ranging from degenerative mitral | | | | to examine gene expression in mouse tissues as part |
| valve disease (DMVD), to transcriptional changes | | | | of a NIH funded Mutant Mouse Regional Resource |
| associated with oxidative stress in the mitochondria. | | | | Center. |
| Co-author Brian Parr, Ph.D. brings a wealth of basic | | | | # # # |
| science expertise to the project with a number of | | | | About Advanced Restoration Technologies Inc., DBA |
| peer-reviewed papers describing novel gene | | | | HairGenesis® |
| transcription and protein expression profiles in the | | | | Combining scientific validation with the safety of |
| Wnt and Frizzled pathways. | | | | natural ingredients, ART's product line HairGenesis® |
| Study co-author Geno Marcovici, Ph.D. has been | | | | represents a unique therapeutic platform in the hair |
| active in the hair loss field for more than a decade. | | | | loss treatment category. Prior to focusing on basic |
| His research efforts include the first published clinical | | | | science research, ART established a 10-year track |
| trial successfully testing naturally derived 5 alpha | | | | record as a surgical center for IRB-monitored clinical |
| reductase inhibitors in the setting of pattern hair loss. | | | | investigation, testing new drugs as well as medical |
| Explaining the importance of validating ART's | | | | devices. ART-based published studies include those |
| proprietary formulations Marcovici notes that "[a]side | | | | undertaken on behalf of Organogenesis, Canton, MA |
| from HairGenesis®, the naturally-derived hair | | | | and Procyte Corporation, Kirkland, WA. It was from |
| treatments commercially available offer little or no | | | | this research platform that Hair Genesis™ was |
| objective evidence that they work. On the other | | | | originally conceived and created. |